Publication Name	World Journal of Clinical Cases
Manuscript ID	48582
Country	Türkiye

Received	2019-04-24 00:35
Peer-Review Started	2019-05-08 04:07
To Make the First Decision	2019-06-03 03:14
Return for Revision	2019-06-17 03:18
Revised	2019-06-18 11:29
Second Decision	2019-07-12 09:59
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2019-07-20 03:43
Articles in Press	2019-07-20 03:43
Publication Fee Transferred
Edit the Manuscript by Language Editor	2019-08-10 19:11
Typeset the Manuscript	2019-08-20 06:17
Publish the Manuscript Online	2019-08-26 02:56

ISSN	2307-8960 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Case Report
Article Title	Effectiveness of vedolizumab treatment in two different anti-tumor necrosis factor alpha refractory pouchitis: A case report
Manuscript Source	Unsolicited Manuscript
All Author List	Ozlem Ozer Cakir
ORCID	Author(s) ORCID Number Ozlem Ozer Cakir http://orcid.org/0000-0002-5916-8049
Funding Agency and Grant Number
Corresponding Author	Ozlem Ozer Cakir, MD, Assistant Professor, Doctor, Department of Gastroenterology and Hepatology, Alanya Alaaddin Keykubat University, School of Medicine, Kestel yerleşkesi, Antalya 07425, Antalya, Türkiye. tansozlem@yahoo.com
Key Words	Anti-tumor necrosis alpha; Refractory pouchitis; Vedolizumab; Ulcerative colitis; ;
Core Tip	Vedolizumab, a humanized immunoglobulin G1 monoclonal antibody to α4β7 integrin, has been shown to moderate gut lymphocyte trafficking with an efficacy in treatment of both Crohn’s disease and ulcerative colitis. In our patient who had two different anti-tumor necrosis factor refractory pouchitis, the gut-specific immune modulation mediated by vedolizumab treatment resulted in good responses. This case is important because of vedolizumab is the novel ttherapy for refractory pouchitis. However, further large and prospective studies are needed for efficacy and the underlying mechanisms of efficacy of vedolizumab in treatment of refractory pouchitis.
Publish Date	2019-08-26 02:56
Citation	Cakir OO. Effectiveness of vedolizumab treatment in two different anti-tumor necrosis factor alpha refractory pouchitis: A case report. World J Clin Cases 2019; 7(16): 2316-2321
URL	https://www.wjgnet.com/2307-8960/full/v7/i16/ 2316.htm
DOI	https://dx.doi.org/10.12998/wjcc.v7.i16.2316

Full Article (PDF)	WJCC-7-2316.pdf
Full Article (Word)	WJCC-7-2316.docx
CARE Checklist–2016	48582-CARE-Checklist–2016-revision.jpg
Manuscript File	FP6932_de16_CE1MS_edit2 (1).docx
Answering Reviewers	48582-Answering reviewers.pdf
Audio Core Tip	48582-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	48582-Conflict-of-interest statement.pdf
Copyright License Agreement	48582-Copyright license agreement.pdf
Signed Informed Consent Form(s) or Document(s)	48582-Informed consent statement.pdf
Non-Native Speakers of English Editing Certificate	48582-Language certificate.pdf
Peer-review Report	48582-Peer-review(s).pdf
Scientific Misconduct Check	48582-Scientific misconduct check.pdf
Scientific Editor Work List	48582-Scientific editor work list.pdf